Skip to content

Study · Not a test of the peptide alone · 2021

4 results

USP7 regulates the proliferation and differentiation of ATDC5 cells through the Sox9-PTHrP-PTH1R axis.

Dong X, Xu X, Yang C, Luo Y, Wu Y, Wang J

Bone27 Oct 2020Cited by 20 (Europe PMC)

PMID33127578 (opens in a new tab)DOI10.1016/j.bone.2020.115714 (opens in a new tab)PepBankPUB-33127578
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone4

In this study, Abaloparatide (Tymlos) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Abaloparatide (Tymlos).

  1. 01LabNot a test of Abaloparatide (Tymlos) aloneIn vitro (cells)Mechanism

    In ATDC5 cells, abaloparatide supplementation activated PTH1R.

    In plain wordsIn cells, abaloparatide activated the PTH1R receptor.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreasePTH1R activation
    Study

    n: not reported in source

    ATDC5 cells
    Outcome group
    Bone and joint · Musculoskeletal

    Source sentences

    Summary
    Supplementation with abaloparatide activated PTH1R to upregulate proliferation and chondrogenic differentiation but downregulated hypertrophic differentiation.
    1 context sentence
    Summary · context
    Cyclopamine and abaloparatide were used to verify the signalling pathway.

    In this study, Abaloparatide (Tymlos) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Abaloparatide (Tymlos).

  2. 02LabNot a test of Abaloparatide (Tymlos) aloneIn vitro (cells)Mechanism

    In ATDC5 cells, abaloparatide supplementation increased proliferation.

    In plain wordsIn cells, abaloparatide increased cell multiplication.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreaseCell proliferation
    Study

    n: not reported in source

    ATDC5 cells
    Outcome group
    Bone and joint · Musculoskeletal

    Source sentences

    Summary
    Supplementation with abaloparatide activated PTH1R to upregulate proliferation and chondrogenic differentiation but downregulated hypertrophic differentiation.
    1 context sentence
    Summary · context
    Cyclopamine and abaloparatide were used to verify the signalling pathway.

    In this study, Abaloparatide (Tymlos) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Abaloparatide (Tymlos).

  3. 03LabNot a test of Abaloparatide (Tymlos) aloneIn vitro (cells)Mechanism

    In ATDC5 cells, abaloparatide supplementation increased chondrogenic differentiation.

    In plain wordsIn cells, abaloparatide increased differentiation toward cartilage cells.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreaseChondrogenic differentiation
    Study

    n: not reported in source

    ATDC5 cells
    Outcome group
    Bone and joint · Musculoskeletal

    Source sentences

    Summary
    Supplementation with abaloparatide activated PTH1R to upregulate proliferation and chondrogenic differentiation but downregulated hypertrophic differentiation.
    1 context sentence
    Summary · context
    Cyclopamine and abaloparatide were used to verify the signalling pathway.

    In this study, Abaloparatide (Tymlos) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Abaloparatide (Tymlos).

  4. 04LabNot a test of Abaloparatide (Tymlos) aloneIn vitro (cells)Mechanism

    In ATDC5 cells, abaloparatide supplementation decreased hypertrophic differentiation.

    In plain wordsIn cells, abaloparatide decreased hypertrophic differentiation.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    DecreaseHypertrophic differentiation
    Study

    n: not reported in source

    ATDC5 cells
    Outcome group
    Bone and joint · Musculoskeletal

    Source sentences

    Summary
    Supplementation with abaloparatide activated PTH1R to upregulate proliferation and chondrogenic differentiation but downregulated hypertrophic differentiation.
    1 context sentence
    Summary · context
    Cyclopamine and abaloparatide were used to verify the signalling pathway.

    In this study, Abaloparatide (Tymlos) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Abaloparatide (Tymlos).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:25 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.